Where Are We and Where to Next?—The Future of Perianal Crohn’s Disease Management

Perianal fistulizing Crohn’s Disease (pCD) affects about 25% of patients with Crohn’s Disease (CD). It remains a difficult entity to manage with a therapeutic ceiling of treatment success despite improving medical and surgical management. The refractory nature of the disease calls for an imminent ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Anandabaskaran, Sulak, Hanna, Luke, Iqbal, Nusrat, Constable, Laura, Tozer, Phil, Hart, Ailsa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573672/
https://www.ncbi.nlm.nih.gov/pubmed/37835022
http://dx.doi.org/10.3390/jcm12196379
Descripción
Sumario:Perianal fistulizing Crohn’s Disease (pCD) affects about 25% of patients with Crohn’s Disease (CD). It remains a difficult entity to manage with a therapeutic ceiling of treatment success despite improving medical and surgical management. The refractory nature of the disease calls for an imminent need to better understand its immunopathogenesis and classification to better streamline our treatment options. In this article, we overview the current state of pCD management and discuss where the future of its management may lie.

Ejemplares similares